These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2189589)

  • 21. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice.
    Emanuel N; Kedar E; Bolotin EM; Smorodinsky NI; Barenholz Y
    Pharm Res; 1996 Jun; 13(6):861-8. PubMed ID: 8792423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Basic study on hepatic artery chemoembolization and tumor selective drug targeting by temperature-sensitive liposome with local hyperthermia].
    Ueno M; Zou YY; Yamagishi M; Horikoshi I
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3735-8. PubMed ID: 2596857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting liver tumors by administering liposomal doxorubicin into the hepatic artery.
    Zou Y; Horikoshi I; Ueno M; Gu X; Perez-Soler R
    Int J Cancer; 1992 May; 51(2):232-7. PubMed ID: 1568791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model.
    Zocchi E; Tonetti M; Polvani C; Guida L; Benatti U; De Flora A
    Proc Natl Acad Sci U S A; 1989 Mar; 86(6):2040-4. PubMed ID: 2928317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues.
    Zara GP; Cavalli R; Bargoni A; Fundarò A; Vighetto D; Gasco MR
    J Drug Target; 2002 Jun; 10(4):327-35. PubMed ID: 12164381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
    Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
    Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice.
    Nakada Y; Fattal E; Foulquier M; Couvreur P
    Pharm Res; 1996 Jan; 13(1):38-43. PubMed ID: 8668676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles.
    Wohlfart S; Khalansky AS; Bernreuther C; Michaelis M; Cinatl J; Glatzel M; Kreuter J
    Int J Pharm; 2011 Aug; 415(1-2):244-51. PubMed ID: 21641983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
    Yu JM; Li YJ; Qiu LY; Jin Y
    J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.
    Barraud L; Merle P; Soma E; Lefrançois L; Guerret S; Chevallier M; Dubernet C; Couvreur P; Trépo C; Vitvitski L
    J Hepatol; 2005 May; 42(5):736-43. PubMed ID: 15826724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
    Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
    Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased bone marrow toxicity of doxorubicin bound to nanoparticles.
    Gibaud S; Andreux JP; Weingarten C; Renard M; Couvreur P
    Eur J Cancer; 1994; 30A(6):820-6. PubMed ID: 7917543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
    Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
    Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of the doxorubicin magnetic nanoconjugate in mice. Effects of the nonuniform stationary magnetic field.
    Mykhaylyk OM; Dudchenko NO; Dudchenko AK
    Ukr Biokhim Zh (1999); 2005; 77(5):80-92. PubMed ID: 16846074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model.
    Okada M; Kudo S; Miyazaki O; Saino T; Ekimoto H; Iguchi H; Hirano S; Kuboki H; Kadosawa H; Takeuchi T
    Br J Cancer; 1995 Mar; 71(3):518-24. PubMed ID: 7880733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture.
    Bennis S; Chapey C; Couvreur P; Robert J
    Eur J Cancer; 1994; 30A(1):89-93. PubMed ID: 8142172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles].
    Gibaud S; Weingarten C; Andreux JP; Couvreur P
    Ann Pharm Fr; 1999 Jul; 57(4):324-31. PubMed ID: 10472705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Verapamil-reversing concentrations induce blood flow changes that could counteract in vivo the MDR-1-modulating effects.
    Ramirez LH; Munck JN; Zhao Z; Bognel C; Ricard M; Ardouin P; Rougier P; Gouyette A
    Cancer; 1994 Aug; 74(3):810-6. PubMed ID: 7913658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effect of liposome-entrapped adriamycin administered via the portal vein.
    Ichino T; Yotsuyanagi T; Mizuno I; Akamo Y; Yamamoto T; Saito T; Kurahashi S; Tanimoto N; Yura J
    Jpn J Cancer Res; 1990 Oct; 81(10):1052-6. PubMed ID: 2121678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.